Vasomune is a true bench-to-bedside story. From its academic beginnings to it becoming a clinical company I have been involved in all aspects of the Vasomune’s development from drug discovery, all pre-clinical scientific endeavours, CMC and all primary, secondary pharmacology and toxicology reporting. With the team’s combined efforts, Vasomune’s Investigational New Drug (IND) application was granted allowance by the FDA transitioning Vasomune from a pre-clinical to clinical biotech company. With a combined 20 years experience in academia and industry, I have authored and collaboratively published on vascular biology, host response, angiogenic signaling and cancer. I currently work to connect with investors, KOLs in academia and the military to support our Phase I and II endeavours and to shepherd new pre-clinical indications and assets within our Discovery and R&D framework.Vasomune Therapeutics, Inc., is a private biopharmaceutical firm based in downtown Toronto. Our primary lead candidate drug is part of the fight against ARDS - learn more here:https://vasomune.com/vasomune-lead-investigational-medication-is-connected-to-fight-against-coronavirus.Keywords: Biotech R&D experience, startup, strategic science and business acumen, adaptable, agile and focused.